RoviraAWattjesMPTintoreM. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-clinical implementation in the diagnostic process. Nature Reviews Neurology2015; 11(8): 471–482.
2.
WattjesMPRoviraAMillerD. Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis–establishing disease prognosis and monitoring patients. Nature Reviews Neurology2015; 11(10): 597–606.
KortewegTUitdehaagBMKnolDL. Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. Eur Radiol2007; 17(1): 67–71.
5.
Erbayat AltayEFisherEJonesSEHara-CleaverCLeeJCRudickRA. Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol2013; 70(3): 338–344.
6.
WattjesMPRichertNDKillesteinJ. The chameleon of neuroinflammation: Magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. Mult Scler2013; 19(14): 1826–1840.
7.
YousryTAMajorEORyschkewitschC. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. New Engl J Med2006; 354(9): 924–933.
8.
McGuiganCCranerMGuadagnoJ. Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: Recommendations from an expert group. J Neurol Neurosur Ps2016; 87(2): 117–125.
9.
BergerJRAksamitAJCliffordDB. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology2013; 80(15): 1430–1438.
10.
WijburgMTWitteBIVennegoorA. MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. J Neurol Neurosur Ps2016; 87(10): 1138–1145.
